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Abstract: Bloodstream infections (BSIs) are among the leading infections in critically ill 
patients. The case-fatality rate associated with BSIs in patients admitted to intensive care units 
(ICUs) reaches 35%–50%. The emergence and diffusion of bacteria with resistance to antibiot-
ics is a global health problem. Multidrug-resistant bacteria were detected in 50.7% of patients 
with BSIs in a recently published international observational study, with methicillin resistance 
detected in 48% of Staphylococcus aureus strains, carbapenem resistance detected in 69% of 
Acinetobacter spp., in 38% of Klebsiella pneumoniae, and in 37% of Pseudomonas spp. Prior 
hospitalization and antibiotic exposure have been identified as risk factors for infections caused 
by resistant bacteria in different studies. Patients with BSIs caused by resistant strains showed 
an increased risk of mortality, which may be explained by a higher incidence of inappropriate 
empirical therapy in different studies. The molecular genetic characterization of resistant bacteria 
allows the understanding of the most common mechanisms underlying their resistance and the 
adoption of surveillance measures. Knowledge of epidemiology, risk factors, mechanisms of 
resistance, and outcomes of BSIs caused by resistant bacteria may have a major influence on 
global management of ICU patients. The aim of this review is to provide the clinician an update 
on BSIs caused by resistant bacteria in ICU patients.
Keywords: bloodstream infections, multidrug resistant, antibiotic, intensive care unit, 
MDR, ICU
Introduction
Bloodstream infections (BSIs) are among the leading acquired infections in intensive 
care unit (ICU) patients.1 BSIs may be the consequence of the bloodstream diffusion 
of bacteria from a localized infection (secondary BSI) or may be the only identifiable 
infectious process (primary BSI). Antimicrobial therapy is the mainstay of treatment 
of BSIs, along with management of severe sepsis and septic shock that may eventually 
develop.2 During these last few years, clinicians have witnessed a growing incidence of 
BSIs by bacteria with resistance against commonly used antimicrobials.3 A multidrug-
resistant (MDR) microorganism has been defined as an isolate with nonsusceptibility 
to at least one agent in three or more antimicrobial categories. Extensive drug-resistant 
(DR) microorganisms exhibit susceptibility to only one or two antimicrobial catego-
ries, whereas pan-DR isolates are those microorganisms resistant to all agents from 
all antimicrobial categories.4 Emergence of resistance among bacteria is considered a 
public health problem worldwide.5 BSIs caused by MDR microorganisms are associ-
ated with excess mortality, which may be attributed, at least in part, to the delay in 
appropriate therapy institution.6–8 Emergence of resistant bacteria in the ICU implies 
Infection and Drug Resistance 2015:8submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
288
Russotto et al
an even higher challenge for the clinician, dealing with seri-
ously ill patients, who need prompt institution of effective 
antimicrobial therapy in a setting of higher prevalence of 
resistant isolates, broad-spectrum antibiotic, use and ease 
of cross-transmission of resistant microorganisms.2,9,10 The 
clinician should be aware of the main risk factors for BSIs 
sustained by resistant bacteria in the ICU, the most commonly 
met resistant species according to different geographic areas, 
and their mechanisms of resistance. The aim of this review is 
to provide the clinician an update on BSI caused by resistant 
bacteria in ICU patients.
Epidemiology of BSIs caused  
by resistant bacteria
BSIs are among the leading infections in ICUs. In an inter-
national study of the prevalence and outcomes of infections 
in ICUs, BSIs were observed in 15% of infected patients and 
represented the third-most commonly met infection.1 The tra-
ditional classification of BSIs between community-acquired 
and hospital-acquired is being reconsidered in light of the 
evolving health care-system organization. A growing propor-
tion of patients, with older age and several comorbidities, are 
treated as outpatients, with a shift of health care services from 
hospitals to the community with different out-of-hospital 
facilities.11,12 In this sense, health care-associated BSIs have 
been defined as those occurring in patients living in a nursing 
home or long-term care facilities, receiving health care at 
home, under hemodialysis, intravenous chemotherapy, wound 
care, or enteral nutrition, or who recently accessed an acute 
care hospital.11 Approximately one in five BSIs diagnosed at 
ICU admission may be classified as health care-associated 
BSIs.13 Pathogens responsible for health care-associated 
BSIs are similar to those isolated from hospital-acquired 
BSIs, with a higher risk of resistant isolates compared to 
community-acquired BSIs. A higher incidence of inappropri-
ate empirical therapy and a trend of increased mortality has 
also been detected in different studies.13,14 A recently pub-
lished international observational study provided information 
about hospital-acquired BSIs from 1,156 ICU patients world-
wide.10 Among total microorganisms causing BSI, 57.6% 
were Gram-negative and 33.4% were Gram-positive. MDR 
bacteria caused BSIs in 50.7% of patients, and extensive DR 
bacteria were detected in 22% of patients. Among Gram-neg-
ative bacteria, carbapenem resistance was detected in 69% of 
Acinetobacter spp, 38% of Klebsiella pneumoniae, and 37% 
of Pseudomonas spp. Among Gram-positive bacteria, 48% 
of Staphylococcus aureus isolates were methicillin-resistant 
Staphylococcus aureus (MRSA), and 23% of Enterococcus 
faecium isolates were vancomycin-resistant enterococci 
(VRE). With regard to the source of BSIs, in 21.1% they was 
attributed to the respiratory tract, and in 21.4% BSIs were 
catheter-related. In 23.7% of total patients, no clear source 
of infection was identified. These data are similar to those of 
the recently published French national network REA RAISIN 
of ICU-acquired bacteremia (29.2% catheter-related, 18% 
lower respiratory tract infections).10,15 According to a large 
observational study investigating the trend of BSIs caused 
by resistant bacteria over a period of 10 years, resistant 
isolates represented an additional burden of disease rather 
than substituting susceptible bacteria as the cause of BSIs.3 
In the modern globalized world, antibiotic-resistant bacteria 
can be easily distributed across countries by human travelers, 
animal and insect vectors, agricultural products, and water.16 
Analysis of genetic material encoding antibiotic resistance 
has been used for tracing the diffusion of resistant strains 
both at a local and international level.17 An example is the 
worldwide distribution of MDR staphylococci from very few 
resistant clones.18 Rapid detection of resistant bacteria and 
their genetic characterization through molecular techniques 
is therefore a pivotal component of surveillance and control 
of diffusion of resistant bacteria from a single institution to 
a global level.19,20
Risk factors for BSI caused  
by resistant bacteria
Patients in ICUs have different risk factors for BSI devel-
opment, including greater severity of illness, disruption of 
anatomical barriers (ie, use of invasive devices, surgery), and 
impaired immunological response.2 Patients with a central 
vein catheter (CVC) have additional risk factors for catheter-
related BSIs (inadequate adoption of a sterile technique, 
inexperience of the operator, site of insertion, colonization 
of the insertion site, contamination of the catheter hub, and 
duration of catheter placement).21–23 Different observational 
studies have described risk factors for BSIs caused by resis-
tant bacteria.10–12,24 In general, prior antibiotic exposure and 
hospitalization, residency in nursing home and in long-term 
care facilities, and other described risk factors for health 
care-related BSIs are associated with an increased risk of 
developing a BSI caused by resistant microorganisms.13,25–27 
In a retrospective study of patients with severe sepsis and sep-
tic shock attributed to bacteremia caused by Gram-negative 
microorganisms, prior antibiotic exposure was associated 
with a reduced susceptibility to cefepime, piperacillin/
tazobactam, carbapenems, ciprofloxacin, and gentamicin. 
Moreover, patients with recent antibiotic exposure more 
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frequently received inappropriate empirical antimicrobial 
therapy and had higher hospital mortality.26 Patients with 
BSIs caused by carbapenem-resistant K. pneumoniae more 
frequently had a CVC or urinary catheter compared to 
patients with BSIs caused by susceptible microorganisms, 
received renal replacement therapy or prior antibiotic treat-
ment, and were more likely hospitalized in a ward with 
other resistant isolates during the 30 days preceding the 
BSI diagnosis.25 Colonization was identified as a significant 
risk factor for subsequent development of bacteremia by 
Acinetobacter baumannii in different studies.9,28,29 Patients 
were frequently colonized by MDR A. baumannii after 
approximately 7 days from ICU admission, with respiratory 
and urinary tracts the most commonly detected colonized 
sites.9 Reported risk factors for subsequent development of 
bacteremia by MDR A. baumannii in previously colonized 
patients were respiratory failure at ICU admission treated 
with invasive mechanical ventilation, recent CVC insertion, 
prior antibiotic therapy, and development of bacteremia 
caused by other microorganisms after MDR A. baumannii 
colonization.29 Knowledge of risk factors for BSIs caused 
by resistant bacteria may have a major influence on global 
management in ICUs, from source-control and surveillance 
measures to appropriate antibiotic treatment.19
Mechanisms of antibacterial  
drug resistance
Antibiotic resistance is a complex phenomenon that encom-
passes recognized in vitro mechanisms and their phenotypic 
expression, but also – at the clinical level – infection site, 
pharmacodynamic/pharmacokinetic properties of the specific 
antibiotic, modification of these pharmacological profiles in 
the critically ill patient, and immune status.30,31 Resistance 
patterns of bacteria at a cellular level may be generally 
classified as follows: altered target site, namely modifica-
tion of the molecule that is the target of the antimicrobial 
action; decreased antimicrobial uptake through decreased 
permeability to the antimicrobial or its elimination by efflux 
pumps; bypass pathways, which overcome the inhibition 
caused by the antibiotic molecule; and inactivation of the 
antimicrobial molecule through the production of enzymes 
that inactivate the drug.31 Antibiotic resistance may represent 
an intrinsic property of different bacteria (eg, low perme-
ability to some molecules), or rather may be acquired as a 
consequence of antibiotic pressure or mobile genetic element 
transmission.32,33
Table 1 summarizes the most commonly described 
resistance mechanisms of bacteria against frequently used 
antibacterial agents in ICU, with the corresponding genes 
identified to date.
Enterococcus spp.
Enterococci are Gram-positive, facultatively anaerobic, 
opportunistic bacteria. E. faecalis and E. faecium are the 
leading species responsible of human disease. VRE, which 
emerged during the late 1980s,34 are among the major health 
care-associated MDR organisms.10 Enterococci are normal 
components of the human intestinal flora, but may become 
responsible for serious infections, such as BSIs and intra-
abdominal and surgical site infections, especially among 
immunocompromised patients.35 These microorganisms 
represent the third-most prevalent nosocomial pathogens 
worldwide, and acquired resistance to penicillin/ ampicillin, 
aminoglycosides, and glycopeptides are reported in an 
increasing number of isolates, causing a serious problem in 
choosing an appropriate therapy.36 All Enterococcus spp., 
including E. faecalis and E. faecium, are naturally resistant 
to several antibiotics, such as cephalosporins, clindamy-
cin, cotrimoxazole, and aminoglycosides.37 Mechanisms 
of glycopeptide resistance in enterococci have been well 
investigated, and to date we know of nine mobile gene clus-
ters that mediate the resistance: VanA, VanB, VanC, VanD, 
VanE, VanG, VanL, VanM, and VanN. VanA resistance is 
the most prevalent, and confers high-level resistance to all 
glycopeptides by altering the terminal sequence of cell-wall 
precursors, thus lowering their binding affinity, while the 
VanB phenotype is only resistant to vancomycin.37 VRE 
isolates exhibit a genetic “pathogenicity island”, coding for a 
putative enterococcal surface protein.38 This protein produces 
thicker and DR biofilms, and its expression in E. faecium is 
regulated by temperature, promoting initial colonization and 
aiding in biofilm formation. Thanks to the ability to colonize 
gut, skin, and inanimate surfaces, this trait is likely to pro-
mote the infection of indwelling medical devices, of which 
enterococci are frequently associated.39 Of note, vancomycin-
resistance genes can be transferred from enterococci to other 
organisms, causing the emergence of vancomycin-resistant 
S. aureus (VRSA).40
S. aureus
S. aureus is a Gram-positive, facultative anaerobic pathogen, 
with both hospital- and community-acquired strains. It is part 
of the microbiota of the skin, and it is most commonly iso-
lated from moist areas, such as the anterior nares and axillae.41 
Traditionally opportunistic, many S. aureus strains are now 
aggressively pathogenic, causing a wide range of diseases, 
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Table 1 Mechanisms of resistance against most commonly used antimicrobial agents and corresponding genes expressed by bacteria
Drugs Mechanism of resistance Genes Microorganism
Penicillins Altered target site mecA S. aureus
enzymatic inactivation Inducible ampC (intrinsically resistant) Enterobacter spp.
Cephalosporins Increased elimination AdeABC/AbeM A. baumannii
enzymatic inactivation ampC/LysR-type P. aeruginosa
enzymatic inactivation blaCTX-M/ampC E. coli
enzymatic inactivation ampC Enterobacter spp.
Aminoglycosides Altered target site armA and rmtB K. pneumoniae
Altered target site armA and rmtB E. coli
Increased elimination 
Altered target site
AdeABC/AbeM 
armA
A. baumannii
Glycopeptides Altered target site vanA-vanN enterococci; S. aureus
Lincosamides enzymatic inactivation 
Increased elimination
erm genes, linB (intrinsic and inducible resistance) 
msrA-msrC
enterococci
Tetracyclines Increased elimination tet(A), tet(A)1, acrAB K. pneumoniae
Altered target site tetA–tetB A. baumannii
Cotrimoxazole Bypass pathway No genes involved (intrinsically resistant) enterococci
Altered target site sul1, sul2, sul3, dfrA1, dfrA5 K. pneumoniae
Fluoroquinolones Altered target site/bypass pathway qnr-like (intrinsically resistant) enterococci
Altered target site/bypass pathway qnr K. pneumoniae
Increased elimination 
Altered target site
AdeABC/AbeM 
gyrA
A. baumannii
Altered target site gyrA P. aeruginosa
Altered target site 
Altered target site 
Altered target site/bypass pathway
gyrA/gyrB/parC/marR 
ompF/ompC 
qnr
E. coli
Carbapenems enzymatic inactivation blaKPC/blaSMe/blavIM 
blaIMP/blaNDM/blaOXA
K. pneumoniae
enzymatic inactivation ampC/eS OXA A. baumannii
enzymatic inactivation blaIMP/blavIM/blaSPM/blaKPC 
ampC/LysR-type 
blaOXA
P. aeruginosa
enzymatic inactivation blaNDM E. coli
enzymatic inactivation blaKPC/blaOXA/blaIMP/blavIM 
blaCTX/ampC
Enterobacter spp.
Tigecycline Increased elimination AdeABC/AbeM 
AdeIJK
A. baumannii
Increased elimination AdeABC/AdeIJK P. aeruginosa
Polymyxins Altered target site pmrA/pmrB 
phoP/phoQ 
mgrB
K. pneumoniae
Altered target site pmrA/pmrB 
lpxA/lpxC/lpxD
A. baumannii
Altered target site pmrA/pmrB 
phoP/phoQ 
cprR/cprS 
colR/colS
P. aeruginosa
Abbreviations: S. aureus, Staphylococcus aureus; A. baumannii, Acinetobacter baumannii; P. aeruginosa, Pseudomonas aeruginosa; E. coli, Escherichia coli; K. pneumoniae, Klebsiella 
pneumoniae.
from skin and wound infections to severe illnesses, such as 
BSIs and soft-tissue and bone infections.41,42 As enterococci, 
S. aureus also frequently causes chronic infections by form-
ing biofilms, and this is the leading cause of chronic infec-
tions associated with indwelling medical devices.43 MRSA is 
a major pathogen in both health care and community settings, 
and its resistance is conferred by the acquisition of one of 
several staphylococcal cassette chromosome mec elements 
that carry a gene (mecA) that encodes a penicillin-binding 
protein (PBP2a) with low affinity for β-lactam antibiotics.44,45 
One of the most challenging issues in the evolution of MRSA 
epidemiology is the emergence and spread of community-
acquired MRSA. These strains are generally susceptible to 
a wider spectrum of non-β-lactam antibiotics compared to 
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hospital-acquired MRSA, but they often carry the genes for 
Panton–Valentine leukocidin.46,47 First-line treatment for 
MRSA infections is glycopeptide antibiotics (ie, vancomycin 
or teicoplanin). However, the intensive selective pressure 
caused the emergence of vancomycin-intermediate S. aureus 
and VRSA.42 Vancomycin-intermediate S. aureus strains have 
evolved as a result of fundamental changes in cell-wall thick-
ness and composition, trapping vancomycin and reducing its 
permeation to the site of action. VRSA is far less common, 
and is characterized by an acquired resistance from the VRE 
vanA gene, which alters the terminal sequence of cell-wall 
precursors, making them poor substrates for vancomycin and 
teicoplanin. MDR VRSA isolates exhibit both mecA and vanA 
resistance genes, with resistance being conferred through the 
same mechanisms as MRSA and VRE, respectively.48
enterobacteriaceae
The emergence of resistance in Enterobacteriaceae is 
considered an alarming health threat.49 During these last 
few years, a growing number of K. pneumoniae, E. coli, 
and Enterobacter spp. have developed resistance against 
third-generation cephalosporin, due to extended-spectrum 
β-lactamases (ESBLs). ESBLs evolved from BLs, which 
are frequently expressed in Gram-negative bacteria (TEM-1, 
TEM-2, SHV-1) and are responsible for resistance against 
ampicillin, amoxicillin, and early generations of cepha-
losporins.49,50 Mutations in genes encoding these BLs led 
to the evolution of new enzymes, able to also hydrolyze 
third-generation cephalosporins and aztreonam. More than 
700 ESBLs variants have been identified to date, some of 
which have spread rapidly worldwide.50,51 Different classifi-
cations of BLs have been proposed, though Bush functional 
classification52 and Ampler molecular classification are the 
most commonly used.53 The diffusion of coding genes for 
ESBLs through mobile genetic elements is responsible for 
their ease of diffusion, their transmission in bacteria different 
from Enterobacteriaceae (ie, nonfermenting, Gram-negative 
rods, such as Pseudomonas aeruginosa), and cotransmission 
of genes responsible of resistance against other classes of 
molecules (eg, aminoglycosides).50 Carbapenems are the 
first line treatment of ESBLs producing bacteria, and the 
emergence of carbapenem-resistant isolates leaves limited 
therapeutic options.54,55 Metallo-BLs (MBLs), extended-
spectrum oxacillinases, and clavulanic acid-inhibited 
BLs have all been isolated in Enterobacteriaceae.50 MBLs 
belonging to class B of the Ambler classification (Verona 
imipenemase [VIM], imipenemase [IMP]) have been detected 
in different countries.55 Class D OXA-48 β-lactamases 
have been detected in K. pneumoniae isolates from Turkey, 
Lebanon, and Belgium.55–57 Among class A β-lactamases, 
the most commonly identified enzyme is KPC.55 The first 
KPC- producing K. pneumoniae isolate was detected in North 
Carolina, USA, in 1996.58 This first discovery was followed 
by several other variants (KPC-2 to KPC-7).55 Of note, sev-
eral KPC-producing K. pneumoniae with susceptibility to 
carbapenems have been reported, underlying the need of an 
additional mechanism (eg, poor drug penetration) for full 
expression of drug resistance.59 Apart from enzymatic inacti-
vation of drug molecules, different mechanisms of virulence 
and additional antibiotic-resistance mechanisms have been 
described in Enterobacteriaceae.49 K. pneumoniae is intrin-
sically virulent and capable of invasive infections, due to 
fimbrial adhesins and a thick capsule, which acts as a putative 
antiphagocytic factor.60 Pan-DR strains of KPC-producing 
K. pneumoniae have been reported in the literature, and iso-
lates were resistant to all antibiotic agents tested, including 
carbapenems, polymyxin B, and tigecycline.55 Polymyxins 
are considered the last resort for treatment of infections with 
carbapenem-resistant Gram-negative bacteria.61 However, 
resistance to these compounds has begun to emerge, though 
infrequently. Selective pressure, by the increased use of colis-
tin, and clonal expansion through horizontal transmission, 
have generated clusters of cases infected with multiresistant 
K. pneumoniae strains that have been generally attributed 
to the international epidemic clone ST258. Mono- or mul-
ticlonal  outbreaks of colistin-resistant, KPC-producing 
K.  pneumoniae have been described in hospitals in many coun-
tries, for example Greece, South Korea, the USA, and Italy.62,63 
Altered outer-membrane composition with the phosphate 
groups of lipid A containing five times more l-Ara4N than 
susceptible strains is known to lower the negative charge 
of the outer membrane of K. pneumoniae, leading to the 
reduced interaction of this membrane with polymyxins.64 
A molecular characterization of the structural alterations of 
lipopolysaccharide (LPS) in K. pneumoniae with regard to 
polymyxin resistance has shown the involvement of the phoP/
phoQ and pmrA/pmrB genes.65 One important molecular 
mechanism that leads to the emergence of colistin resistance 
in K. pneumoniae that has recently been discovered is the 
mutation/inactivation of the mgrB gene.66 Disruption of the 
mgrB gene in K. pneumoniae has been identified to play an 
important role in polymyxin resistance in this bacterium.67 
Polymyxins remain most often active against MDR bacte-
ria, and the emergence of colistin resistance in relation to 
increased usage is worrisome, since polymyxins are the last 
remaining therapeutic option in many cases.68
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E. coli are Gram-negative, facultative anaerobes, most 
commonly commensal, but can also become pathogenic, 
producing potentially deadly toxins, including enterohem-
orrhagic verotoxins, such as E. coli O157:H7, which causes 
hemolytic uremic syndrome and renal failure.69 E. coli has 
been one of the most widely antibiotic-susceptible micro-
organisms of the Enterobacteriaceae family, but recently 
horizontal gene transfer has allowed for the rise of highly 
resistant strains.70 This spread of resistance has major rel-
evance, because these strains are among the most common 
Gram-negative bacteria causing infections in humans. Strains 
carrying ESBLs and with high coresistance to fluoroquino-
lones and gentamicin have been rising in Europe.71 Even if 
still uncommonly, in multiple continents E. coli have also 
acquired the NDM-1 enzyme from K. pneumoniae, which 
confers a broad resistance to all BLs, including carbapen-
ems, with the exception of the monobactam aztreonam.72 In 
polymyxin-resistant E. coli, lipid A is typically modified with 
2-aminoethanol and also with l-Ara4N.73
Enterobacter is a genus of Gram-negative, facultative 
anaerobic, opportunistic pathogens, possessing endotoxins 
and antibiotic resistance through expression of an extensive 
variety of ESBLs and carbapenemases, including KPC, OXA, 
and MBLs.74 Of note, Enterobacter spp. are intrinsically 
resistant to aminopenicillins, cefazolin, and cefoxitin, due to 
the production of constitutive chromosomal AmpC BLs.75
Nonfermenting Gram-negative bacteria
A. baumannii
The most common resistant Acinetobacter species is 
A. baumannii, a Gram-negative, facultative anaerobic, oppor-
tunistic pathogen. It has a thick cell wall that enables it to 
resist dry conditions, high temperature, and pH and nutrient 
changes, surviving for up to 5 months on inanimate objects.76 
A. baumannii is naturally resistant to many antibiotics, due 
to both poor membrane penetration and active efflux pumps. 
Overexpression of the AdeABC and AbeM efflux pumps 
causes broad resistance to cephalosporins, fluoroquinolones, 
aminoglycoside, and tigecycline, and also provides resistance 
to ammonia-based disinfectants.77 Furthermore, A. bauman-
nii isolates produce an exopolysaccharide, leading to biofilm 
formation, and express a powerful, epithelial cell-targeting 
cytotoxin that facilitates colonization.78 MDR A. baumannii 
expresses a variety of BLs, including ESBLs and carbapen-
emases, such as imipenem MBLs and oxacillinases.79 Among 
naturally occurring BLs, an AmpC-type cephalosporinase and 
OXA-51/69 variants have been identified. These enzymes, 
once overexpressed, may be involved in reduced susceptibility 
to carbapenems. Most acquired BLs belong to class B or class 
D of the Ambler classification. OXA-23-like enzymes are the 
most widespread in A. baumannii worldwide, and these bac-
teria are the most common sources of nosocomial outbreaks 
with carbapenem-resistant A. baumannii.80 A. baumannii 
worldwide shows high-level resistance to all aminoglycosides 
by decreased outer-membrane permeability, active efflux 
pumps, and amino acid substitutions in ribosomal proteins.31 
In P. aeruginosa and A. baumannii, a single mutation in 
the gyrA gene encoding DNA gyrase is sufficient to confer 
clinically high-level resistance to fluoroquinolones. Of note, 
decreased susceptibility to this class of molecules is also due 
to low permeability and efflux-pump activity.81 Resistance to 
tigecycline has been noted on several occasions, and might 
be due to upregulation of the AdeABC and AdeIJK multi-
drug efflux-pump systems.82 Tigecycline-resistance levels in 
A. baumannii isolates may increase during therapy in cases of 
brief exposure to the drug, compromising its efficacy.82,83 Two 
mechanisms of resistance to colistin have been described in 
A. baumannii. The first consists of alterations of the lipid A 
component of LPS resulting from mutations in the PmrAB 
two-component system.32,84 The second resistance mechanism 
is the complete loss of LPS production resulting from muta-
tions in the lpxA, lpxC, and lpxD genes, encoding the enzymes 
that catalyze the first steps in LPS biosynthesis.85
P. aeruginosa
P. aeruginosa is a Gram-negative, rod-shaped bacterium, 
a facultative anaerobic, opportunistic pathogen surviving 
in microaerobic conditions, such as the thick mucus of 
lungs of cystic fibrosis patients. The ubiquity and survival 
capacity in extreme environments, like antimicrobial solu-
tions of acetate-buffered benzalkonium chloride, are major 
determinants of outbreaks of nosocomial infections. It has a 
high propensity to form biofilms. Its outer-membrane porins 
make it impermeable and resistant to many antibiotics.86,87 
P. aeruginosa is notoriously resistant to fluoroquinolones 
as a result of target mutations on DNA gyrase and/or topoi-
somerase IV.33 Many BLs, encoded by plasmids or chro-
mosomally integrated transposons, have been reported (eg, 
IMP, VIM, KPC, and SPM metallocarbapenemases).88 An 
acquired ceftazidimase ESBL called PER-1 is widespread in 
P. aeruginosa isolated in Turkey.89 IMP and VIM enzymes 
are integron-associated and can be plasmid-mediated and 
transferable, although chromosomal gene integration is 
common.88 IMP-1 was first reported in Enterobacteriaceae 
and P. aeruginosa in Japan and is now globally distributed, 
suggesting horizontal transfer of blaIMP-1 between unrelated 
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Gram-negative species.79 VIM-1 was the first MBL identified 
in P. aeruginosa and has been reported in several European 
countries. However, VIM-2 is now the most widespread 
MBL as a source of multiple outbreaks.90 The BL SPM is 
quite different from VIM and IMP, and represents a new sub-
family of MBLs, highly resistant to all anti-Gram-negative 
antibiotics except colistin.91 Intrinsic to P. aeruginosa is a 
chromosomal gene encoding an AmpC-type cephalospori-
nase, associated with a LysR-type regulatory gene with which 
some BL molecules may interact, leading to overexpression 
of the AmpC gene. Selection of mutants overproducing the 
AmpC gene is frequently observed in P. aeruginosa, leading 
to acquired resistance to ticarcillin, piperacillin, and broad-
spectrum cephalosporins (ceftazidime).83,92 P. aeruginosa 
produces a naturally occurring class D BL, OXA-50, that 
does not contribute to the overall BL-resistance pattern of 
P. aeruginosa, except for latamoxef.93 Most of the class D BLs 
able to hydrolyze expanded-spectrum cephalosporins have 
been identified, and there are two main types of expanded-
spectrum class D BLs (ES-OXAs).94 OXA-18, which is 
inhibited by clavulanic acid, was the first identified ES-OXA 
in a P. aeruginosa isolate in Paris, from a patient previously 
hospitalized in Sicily.95 Only two acquired class D BLs, com-
promising the efficacy of carbapenems, have been reported 
from P. aeruginosa: OXA-40 and OXA-198.96,97 Resistance 
to tigecycline has been noted on several occasions, and 
might be due to upregulation of the AdeABC and AdeIJK 
multidrug efflux pumps acting synergistically.98 Acquisition 
of polymyxin resistance is mostly related to modifications 
of the biosynthesis of the lipid A component of LPS. This 
resistance is mediated by a complicated regulatory genetic 
network, such as PmrAB, PhoPQ, ParRS, CprRS, and ColRS, 
which is currently under investigation worldwide.61
Outcomes
The overall case-fatality rate associated with BSIs is 
15%–20%, but reaches 35%–50% when patients with ICU 
admission are considered.2 In most observational studies 
investigating the epidemiology and outcomes of BSIs due 
to resistant bacteria, inappropriate antimicrobial therapy 
is independently associated with an increased mortality 
after correction for severity of illness and other potential 
confounders.8,10,25,99 The risk of inappropriate empirical 
therapy increases with the prevalence of resistant micro-
organisms.25 It is generally accepted that the increased risk 
of mortality attributable to BSIs due to resistant isolates 
is related to inappropriate therapeutic choices, rather than 
intrinsic enhanced virulence of resistant microorganisms.25 
The overall mortality of patients with BSIs due to 
carbapenem-resistant K. pneumoniae was 23% at 7 days 
and 60% at the end of hospitalization in a retrospective 
observational study. Lack of microbiologic eradication at 
7 days was associated with an increased 30-day mortality.100 
A higher infection-related mortality was detected in patients 
with BSIs caused by carbapenem-resistant K. pneumoniae 
compared to those with ESBL K. pneumoniae or susceptible 
strains. This increased mortality may be explained by the 
higher proportion of patients with ineffective antimicrobial 
therapy in the carbapenem-resistant group.25 Apart from pre-
viously reported risk factors (recent history of hospitaliza-
tion, critical illness at presentation, inappropriate empirical 
therapy), postantibiogram antimicrobial regimens had an 
influence on 30-day mortality from carbapenem-resistant 
K. pneumoniae BSIs, with a higher risk of mortality observed 
in monotherapy-treated patients compared to patients treated 
with combination therapy, especially when the combination 
regimen included a carbapenem.54 The unexpected observa-
tion of improved outcomes when carbapenemase-producing 
isolates of K. pneumoniae are treated with carbapenems 
confirmed previously reported data from case reports and 
retrospective studies.101,102
Conclusion
BSIs are among the leading causes of infections in ICU 
patients. An increasing number of BSIs are caused by 
resistant bacteria in the ICU setting. The clinician should be 
aware of the risk factors for BSIs caused by resistant bacteria, 
common resistance mechanisms, and their diffusion for the 
global management of critically ill patients, from surveil-
lance measures to source control and appropriate antibiotic 
treatment.
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